Back to Search
LAUREL WITTE, DO
DO
Physical Medicine & Rehabilitation Physician
NPI: 1417715996Individual
Specialties, Licenses & Credentials
Physical Medicine & Rehabilitation PhysicianPrimary
Physical Medicine & Rehabilitation
Code: 208100000X
5151017510(MI)
Research & Publications (20)
Reducing the use of seclusion and restraint. A Michigan provider reduced its use of seclusion and restraint by 93% in one year on its child and adolescent unit.
PMID 18524369·Behav Healthc·2008
8-other
Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?
PMID 19057211·Curr Opin Urol·2009
6-review
Cholinergic innervation and muscarinic receptors in the human prostate.
PMID 18160204·Eur Urol·2008
6-review
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
PMID 19528458·Anticancer Res·2009
7-preclinical
Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.
PMID 19484148·Neoplasia·2009
7-preclinical
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
PMID 19584274·Cancer Res·2009
7-preclinical
Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells.
PMID 19265665·Cell Stem Cell·2009
7-preclinical
Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
PMID 19276250·Clin Cancer Res·2009
7-preclinical
Archaeal diversity at the great salt plains of Oklahoma described by cultivation and molecular analyses.
PMID 19306116·Microb Ecol·2009
8-other
Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
PMID 18765536·Clin Cancer Res·2008
7-preclinical
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines.
PMID 18852148·Mol Cancer Ther·2008
7-preclinical
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
PMID 18772115·Cancer Cell·2008
7-preclinical
[Fibrosing alveolitis with hepatitis C-related cryoglobulinemia].
PMID 18363189·Dtsch Med Wochenschr·2008
5-case
Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat.
PMID 17032939·Am J Physiol Renal Physiol·2007
7-preclinical
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
PMID 17234768·Cancer Res·2007
7-preclinical
IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
PMID 16651440·Cancer Res·2006
7-preclinical
The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.
PMID 16671089·Int J Cancer·2006
7-preclinical
Bonabiline A, a monoterpenoid 3alpha-acyloxytropane from the roots of Bonamia spectabilis showing M3 receptor antagonist activity.
PMID 17089324·Planta Med·2006
7-preclinical
Microalbuminuria and proximal tubule remodeling in the cardiometabolic syndrome.
PMID 17679822·J Cardiometab Syndr·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 JEFFERSON AVE SE
GRAND RAPIDS, MI 49503 - Phone
- (616) 685-6867
Quick Facts
- NPI
- 1417715996
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile